Brought to you by 
Series B brings in $37.5mm for Applied Genetic Technologies
11 Dec 2012
Executive Summary
Applied Genetic Technologies Corp. (gene therapies for retinal diseases) has raised $37.5mm through its Series B venture round. Alta Partners and SR One led the financing and was joined by new investor Osage University Partners and current shareholders InterWest, Intersouth Partners, and MedImmune Ventures. The company will use the money to continue developing a Phase II alpha-1 antitrypsin deficiency therapy and to start working on treatments for achromatopsia and x-linked rentinoschisis.
Deal Industry
- Pharmaceuticals
-
Pharmaceuticals
- Drug Delivery
-
Biotechnology
- Gene Therapy, Cell Therapy
-
Drug Discovery Tools
- Genomics-Proteomics
Deal Status
- Final
Deal Type
-
Financing
- Venture Financing
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Series B brings in $37.5mm for Applied Genetic Technologies
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice